期刊文献+

卡巴他赛合成路线图解

Graphical synthetic routes to cabazitaxel
原文传递
导出
摘要 卡巴他赛(cabazitaxel,1)是一种半合成紫杉烷类化合物,其前体从紫杉树针叶中提取获得,化学名称为苯甲酸{(2α,5β,7β,10β,13α)-4-乙酰基-13-{(2R,3S)-3-[(叔丁氧基羰基)氨基]-2-羟基-3-苯丙酰氧基}-1-羟基-7,10-二甲氧基-9-氧代-5,20-环氧紫杉烷-11-烯-2-基}酯。该药由赛诺菲-安万特公司研发,2010年6月由美国FDA批准上市。
出处 《中国药物化学杂志》 CAS CSCD 2015年第1期74-76,共3页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金项目(21342006)
  • 相关文献

参考文献9

  • 1FDA. Cabazitaxel [ EB/OL]. [2010 -06 - 17 ]. ht- tp://www, fda. gov/aboutfda/centersoffices/officeo fmedicalproductsandtobacco/CDER/ucm216214, htm.
  • 2BOUCHARD H, BOURZAT J D, COMMERON A. Methods of treating cell lines expressing multidrug re- sistance P-glycoprotein : US, 6372780[ P ]. 2002 - 04-06.
  • 3王志宏,钟旭丽.抗前列腺癌新药卡巴他赛的药理与临床评价[J].中国新药杂志,2011,20(9):763-765. 被引量:13
  • 4姚全兴,陈波,李代军,等.一种合成卡巴他赛的方法:中国,102532065[P].2012-07-04.
  • 5白金生,陈大海,陈从均.卡巴他赛的合成方法:中国,CN102675256A[P].2012-09-19.
  • 6ZHANG G N,FANG W S. A new synthesis route of cabazitaxel [ J ]. J Chin Pharm Sci, 2012,21 ( 5 ) : 472 - 476.
  • 7李靖,姚全兴,王信见,陈波.抗肿瘤药卡巴他赛的合成[J].化学与生物工程,2013,30(10):51-53. 被引量:3
  • 8HERVE B, JEAN-DOMINIQUE B, ALAIN C, et al. Taxoids, their preparation and pharmaceutical compo- sitions containing them: US, 5847170 [ P]. 1989 - 03 -21.
  • 9夏彪,邵波,杨巧宾,李勤耕.卡巴他赛关键中间体7β,10β-二甲氧基-10-脱乙酰巴卡汀Ⅲ的合成新方法[J].中国药房,2013,24(1):47-48. 被引量:4

二级参考文献19

  • 1JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2009 [J]. CA Cancer JClin, 2009, 59(4): 225 -249.
  • 2PETRYLAK DP, TANGEN CM, HUSSAIN MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [ J ]. N Engl J Med, 2004, 351(15) : 1513 -1520.
  • 3BERRY DL, MOINPOUR CM, JIANG CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone[ J]. J Clin Oncol, 2006, 24(18) : 2828 -2835.
  • 4Jevtana [ EB/OL ].[ 2010 - 11 - 02 ]. http ://www. accessdata. fda. gov/drugsatfda_docs/label/2010/2010231bl, pdf.
  • 5Sanofi-aventis. XRP6258 investigator's brochure[ M]. Antony (France) : Sanofi-aventis,2000.
  • 6ATTARD G, GREYSTOKE A, KAYE S, et al. Update on tubulin binding agents [ J ]. Pathol Biol( Paris), 2006, 54 ( 2 ) : 72 - 84.
  • 7PIVOTI X, KORALEWSKI P, HIDALGO JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients [J]. Ann Oncol, 2008, 19(9) : 1547 -1552.
  • 8SEBASTIAN J, OUDARD S, OZGUROGLU M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic astration-resistant prostate cancer progressing after ocetaxel treatment: a randomised open-label trial [ J ]. Lancet, 2010, 376 ( 9747 ) : 1147 - 1154.
  • 9FDA. Label approved on 6/17/2010 for JEVTANA , NDA no.201023[EB/OL].[2012-03-27].http://www.Accessda- ta.fda.gov/drugsatfda_docs/label/2010/2010231bl.pdf.2010.
  • 10Didier E, Oddon G, Pauze D, et al. Process for preparing derivatives of the taxoid .family: US, 5962705[P].1999- 10-05.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部